Related Experiment Video
Updated: Mar 26, 2026

Basement Membrane Matrix Encapsulated Cell Aggregation for Investigating Murine Spleen Tissue Formation
Published on: June 28, 2024
Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to
Nikolay Bazhanov1, Joni H Ylostalo2, Thomas J Bartosh3
1Institute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine at Scott & White, 5701 Airport Rd., Temple, TX, 76502, USA. nibazhan@utmb.edu.
Background:
Mesenchymal stem/progenitor cells (MSC) have shown beneficial effects in many models of disease in part by modulating excessive inflammatory and immune responses. Frequently the beneficial effects of MSC persist long after their disappearance from host tissues, suggesting that MSC interact with intermediate cells in the host that relay or amplify their effects. The cells have usually been injected intravenously, but beneficial effects have also been reported with intraperitoneal (IP) injection of MSC. However the fate of IP injection of MSC has not been examined.
Methods:
The fate of the human MSC injected IP into immune-competent mice was studied. In vivo imaging was used to track green fluorescent protein-labeled MSC in the peritoneal cavity. In addition, their retention in peritoneal tissues was measured by real-time polymerase chain reaction for human GAPDH mRNA. To describe the effects of human MSC on the immune system of the peritoneum, the peritoneal lavage, omentum, lymph nodes and mesenteric tissues were collected. Flow cytometry was used to evaluate the immune cell populations, while cytokine/chemokine production was measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Challenge with lipopolysaccharide at 3 days after the administration of MSC was used to evaluate the preconditioning of the immune system.
Results:
Within 20 min, single MSC were no longer detected in peritoneal lavage fluid. Instead they were recovered as aggregates of varying size that contained mouse macrophages and a few B220+ lymphocytes. After 1 day, most of the aggregates containing live MSC were attached to sites throughout the peritoneal cavity including the omentum and mesentery. Less than 0.05 % of the live injected cells were detected in the spleen and jejunal lymph nodes. In all locations, MSC colocalized with mouse macrophages and B220+ lymphocytes. Attachment to the omentum and mesentery was accompanied by the recruitment of immune cells and changes in the production of a series of mouse cytokines. A similar increase in mouse cytokines in the peritoneum was seen after IP injections of human fibroblasts.
Conclusions:
IP injected human MSC rapidly formed aggregates with mouse macrophages and B220+ lymphocytes and attached to the walls of the peritoneal cavity. The formation of the aggregates probably limits access of the cells to the systemic circulation.
Insights
Intraperitoneally injected mesenchymal stem/progenitor cells (MSC) quickly aggregate with host immune cells and attach to the peritoneum. This aggregation likely restricts MSC from entering the bloodstream, influencing their therapeutic effects.
Area of Science:
- Immunology
- Cell Biology
- Regenerative Medicine
Background:
- Mesenchymal stem/progenitor cells (MSC) modulate immune responses, offering therapeutic benefits.
- MSC effects often outlast their presence, suggesting interaction with host cells.
- Intraperitoneal (IP) MSC injection is used, but their fate is unknown.
Purpose of the Study:
- To investigate the fate and immune interactions of human MSC following IP injection in mice.
- To understand how IP-administered MSC influence the peritoneal immune microenvironment.
Main Methods:
- Tracking of GFP-labeled human MSC in mice using in vivo imaging.
- Quantification of MSC retention via human GAPDH mRNA.
- Analysis of peritoneal lavage, omentum, lymph nodes, and mesentery using flow cytometry and qPCR.
- Assessment of immune cell populations and cytokine profiles.
- Immune preconditioning evaluation via LPS challenge.
Main Results:
- MSC rapidly aggregated with mouse macrophages and lymphocytes within 20 minutes.
- Aggregates attached to peritoneal surfaces (omentum, mesentery) within 1 day.
- Minimal MSC (<0.05%) reached systemic circulation (spleen, lymph nodes).
- MSC attachment correlated with immune cell recruitment and altered cytokine production.
Conclusions:
- IP injected human MSC rapidly form aggregates with host immune cells and peritoneal tissues.
- This aggregation mechanism likely limits systemic dissemination of MSC.
- Findings provide insight into the biodistribution and host interaction of IP-administered MSC.
More Related Videos
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
04:53Author Spotlight: Advancing Treatment Approaches with Adipose-Derived Stem Cells
Published on: January 12, 2024